Fri, Dec 26, 2014, 4:45 AM EST - U.S. Markets open in 4 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

  • rob_cos rob_cos Dec 6, 2012 4:17 PM Flag

    Last yr ort told you to sell ASH. Day before ASH was low of month & it went from 61 before ASH to 80+ including to 68 in Dec after ASH

    Actually Oritigia the Thurs before ASH last yr was lLOW FOR THE MONTH $61.29 & it was up from there to 68 in December and all time high in early 2012 over $80.....This yr we also have many catalysts in the next few weeks

    You are thinking about past history. Sure, there are still some who sell before ASH and to me this is why we have not broken 80 this week despite the best November set of catalysts in the history of biotech. But those that did it last yr paid dearly as the day before ASH was low for month 61.29 and it was up from there to 67-68 in Dec after ASH and then to all time high 80+ in first several months of 2012. With Jackie Fouse and other new CELG sr managers, we seem to have broken this ASH pattern of the past and this yrs 250 presentations and posters should deliver good news imo (even normally quiet ASH Tuesday has some very important sessions this yr) and then we still have MANY very near term catalysts including quite a few this month. Expect 80s next week. See last yrs ash stock prices at the bottom of this post starting with the day before ASH


    Even I have been trading some calls in what feels like a continuous loop from low 78s to high 79s but with ASH starting tomorrow, psoriasis and PsA (Palace 4 monotherapy)Ph 3 data coming this month (these two are REAL catalysts) and pomalidomide approval coming soon - well its time to stop selling 79 now ....I am in for the long haul now....


    1) Apremilast Psoriasis top-line data this month

    2) Apremilast PsA Palace 4 is the first all Monotherapy/dmard trial is similar to biologics (important as the first three Ph 3 PsA trials showed amazing safety profile and biologic like ACR 20 scores in a this SUBSET but this is first Ph 3 where entire trial is Monotherapy.

    3) ASH – Pom Ph 3 MM-003 late breaker, NHL, MM-015 update – 250 presentations and posters

    4) Pomalidomide approval – coming early

    5) China Approval of Revlimid in relapsed/refractory MM

    6) Other international approvals or pricing okays in various countries – Brazil, Mexico, Russia, So Korea etc

    7) JP Morgan conference – will be positive imo both 2013 guidance and forward

    8) Stem Cell Crohns data – where oh where is the Stem Cell data?

    9) DETAIL of the amazing Ph 3 Pancreatic Cancer trial in January in San Francisco at the ASCO GI meeting

    10) MM-020 – the largest front line myeloma trial in history Rev-Dex versus Thal-melphalan-P which should have interim look – interesting will be if thalMP arm has more SPMs than Rev-Dex. If this data is really good on the first interim look we could sprint to $100+ as front line EU approval post CHMP debacle is the only reason we are not in the 90s right now imo and the reason we have not been fully paid for the amazing Abraxane and Apremilast news (Bernstein says in the report I posted yesterday this will be a very positive catalyst that will unlock not only front line stock value but also a pent up catch up run for Apremilast, Abraxane and Pomalidomide - which results should have us much higher if it were not for MM-020 pending update - make sure you read that report)


    If you listened to Ortigia and sold before ASH last yr you lost a $7 move in the remaining weeks of Dec 2011 and a $20+ move in the next couple of months

    First | Previous | Next | Last
    Prices
    Date Open High Low Close Volume Adj Close*
    Jan 31, 2012 72.01 72.96 72.01 72.69 2,760,300 72.69
    Jan 30, 2012 71.29 72.72 71.23 72.72 3,386,300 72.72
    Jan 27, 2012 72.73 73.75 71.49 73.37 3,473,100 73.37
    Jan 26, 2012 73.96 74.63 72.34 72.66 3,992,800 72.66
    Jan 25, 2012 73.60 74.20 73.04 73.79 3,777,700 73.79
    Jan 24, 2012 73.24 74.04 72.87 74.02 2,947,300 74.02
    Jan 23, 2012 73.99 74.13 72.96 73.43 2,605,700 73.43
    Jan 20, 2012 72.40 74.75 72.21 73.84 4,991,200 73.84
    Jan 19, 2012 72.84 72.92 72.00 72.21 3,182,800 72.21
    Jan 18, 2012 72.88 73.18 72.48 72.74 3,546,500 72.74
    Jan 17, 2012 73.53 75.11 72.66 73.11 2,945,700 73.11
    Jan 13, 2012 72.76 72.90 71.88 72.63 2,848,600 72.63
    Jan 12, 2012 72.22 73.49 71.21 73.20 5,421,400 73.20
    Jan 11, 2012 70.51 72.31 70.19 72.07 4,311,500 72.07
    Jan 10, 2012 69.19 70.77 68.88 70.26 5,424,400 70.26
    Jan 9, 2012 67.23 68.85 66.87 68.23 6,796,400 68.23
    Jan 6, 2012 68.12 68.45 66.28 67.22 5,765,900 67.22
    Jan 5, 2012 67.97 69.26 67.68 68.51 3,335,800 68.51
    Jan 4, 2012 68.34 68.93 67.68 67.92 2,678,300 67.92
    Jan 3, 2012 68.51 68.96 68.07 68.66 3,033,200 68.66
    Dec 30, 2011 67.67 68.10 67.36 67.60 1,781,000 67.60
    Dec 29, 2011 67.02 67.64 66.85 67.55 1,548,700 67.55
    Dec 28, 2011 68.16 68.16 66.73 66.80 1,937,800 66.80
    Dec 27, 2011 67.27 68.04 67.05 68.01 1,319,400 68.01
    Dec 23, 2011 67.44 67.44 66.60 67.32 1,169,400 67.32
    Dec 22, 2011 66.92 67.10 66.47 67.09 1,888,600 67.09
    Dec 21, 2011 66.56 67.53 65.73 66.55 3,209,900 66.55
    Dec 20, 2011 65.38 66.88 65.36 66.43 5,353,800 66.43
    Dec 19, 2011 63.84 65.00 63.60 64.58 3,186,400 64.58
    Dec 16, 2011 63.43 64.02 62.89 63.69 5,738,700 63.69
    Dec 15, 2011 63.50 63.60 62.98 63.10 3,135,800 63.10
    Dec 14, 2011 63.79 64.61 62.84 63.03 3,713,200 63.03
    Dec 13, 2011 64.10 64.71 63.70 63.96 4,324,200 63.96
    Dec 12, 2011 62.90 64.47 62.56 63.66 5,148,400 63.66
    Dec 9, 2011 61.49 63.71 61.17 63.58 3,986,700 63.58
    Dec 8, 2011 62.39 62.71 61.14 61.29 2,499,700 61.29

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CELG
109.60+3.48(+3.28%)Dec 24 12:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.